Concerning mandatory health-care coverage for hormone replacement therapy for women.
Summary
HB 26-1122 would require Colorado health benefit plans and the state Medicaid program to cover hormone replacement therapy for women experiencing menopause or perimenopause. The bill defines hormone replacement therapy broadly to include treatments such as creams, oral medications, pellets, vaginal devices, or other FDA-approved methods, so long as they are prescribed by a licensed physician. It also prohibits health plans from denying or limiting covered therapy when prescribed according to generally accepted standards of care and bars prior authorization for the treatment.
The coverage mandate would phase in over time. Large employer plans would have to provide coverage for policies issued or renewed on or after January 1, 2027. Individual and small group plans would have to do so on or after January 1, 2028, unless the state would be required to defray the cost under federal law, in which case that portion would not take effect. Medicaid coverage would begin July 1, 2027, subject to federal authorization and federal financial participation. The bill also directs the insurance commissioner to adopt implementing rules.
Impact
The bill would amend Colorado insurance law by adding a new mandatory coverage provision in the state’s health benefit plan statutes and would create a new Medicaid coverage requirement for hormone replacement therapy. It would affect insurers offering large employer, individual, and small group plans, as well as the Department of Health Care Policy and Financing and Medicaid managed care or fee-for-service coverage, depending on implementation. The measure would also constrain utilization management by prohibiting prior authorization for this therapy and by requiring coverage consistent with physician-prescribed standards of care.
Sentiment
The available record shows limited formal debate data, but the bill’s introduction and sponsorship indicate an effort to expand access to menopause-related care. The bill was assigned to the House Health & Human Services Committee, suggesting it was considered as a health coverage measure rather than a broader social policy proposal. However, the last recorded action was a House committee postponement indefinitely on February 24, 2026, which indicates the proposal did not advance in committee and likely faced sufficient concern or lack of support to halt further movement.
Contention
The main points of contention are likely to have centered on the cost and scope of a mandated benefit, especially for insurers and employers who would be required to cover a treatment without prior authorization. Another likely issue is the Medicaid component, which depends on federal authorization and federal financial participation, creating uncertainty about implementation and state fiscal exposure. The bill’s carve-out for individual and small group plans if state defrayal is required also suggests concern about potential obligations under federal health insurance rules. Opponents may have viewed the measure as an added mandate, while supporters likely framed it as improving access to medically necessary care for women experiencing menopause or perimenopause.